Cronos Group
Investor Relations | The Cronos Group
  • Cronos Group (CRON) announced the launch of its first range of products, in partnership with Geocann
  • It will utilize the advanced VESIsorb delivery system to provide better bioavailability and faster absorption
  • Cronos cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach
  • Cronos Group Inc. (CRON) was down 0.99 per cent, trading at C$3.99 at 2.31 pm ET

Cronos Group (CRON) announced the launch of its first range of products in partnership with Geocann.

It will utilize the VESIsorb delivery system to provide better bioavailability and faster absorption. VESIsorb delivers superior pharmacokinetic performance, including rapid absorption, higher plasma concentration, and a greater area under the curve.

Mike Gorenstein, Chairman, President and Chief Executive Officer of Cronos commented on the news.

“Working with Geocann’s technology enables us to expand our product offering. It bring consumers a fast-acting cannabinoid product with a quicker onset than previously available. It improves efficacy, helping enhance and differentiate effect and experience.”

VESIsorb dramatically improves the bioavailability of difficult-to-absorb ingredients, like cannabinoids and terpenes. This patented technology has shown faster absorption in both well-designed pilot and peer-reviewed published studies.

Geocann is the exclusive supplier of the VESIsorb delivery system for cannabinoids, terpenes, and flavonoid formulations. The first VESIsorb formulated product the companies have launched is the CBD Gel Capsules by Lord Jones.

Cronos cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach.

Cronos Group Inc. (CRON) was down 0.99 per cent, trading at C$3.99 at 2.31 pm ET.

More From The Market Online

Telo Genomics and Emery Pharma collaborate

Telo Genomics (TSXV:TELO) collaborates with Emery Pharma to enhance cellular and molecular bioanalytical solutions for clinical research.

UniDoc brings AI to ER patients

UniDoc (CSE:UDOC) expands its AI partnership with DocBox, further integrating predictive analytics into emergency room operations.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.